A study of the mechanism of action of the mild analgesic dipyrone
- PMID: 7942328
- DOI: 10.1007/BF02001915
A study of the mechanism of action of the mild analgesic dipyrone
Abstract
The mechanism of action for the mild analgesics is controversial. While some have proposed that they inhibit prostaglandin synthesis in the central nervous system to interfere with nociceptive mediators in the brain, others have proposed that they act directly on nociceptive neural pathways to produce analgesia. This class of drugs also possesses antipyretic activity. We examined the antipyretic effect of one such drug, dipyrone, because this might elucidate the mechanism of its analgesic activity. In rats implanted with a femoral vein catheter and a cannula guide tube aimed towards the organum vasculosum laminae terminalis (OVLT) in the brain, an i.v. injection of 2 micrograms/kg interleukin-1 beta (IL-1 beta) produced a fever of 0.38 +/- 0.07 degrees C while an injection of 20 ng prostaglandin E1 (PGE) into the OVLT produced a fever of 1.18 +/- 0.18 degrees C. Dipyrone (25 mg/kg, i.v.) decreased the IL-1 beta fever but had no effect on the PGE fever. After pretreatment with the immunoadjuvant, zymosan, the IL-1 beta fevers were enhanced to equal those induced by PGE. Only 0.1 micrograms/kg, i.v. IL-1 beta raised body temperature by 1.20 +/- 0.10 degrees C. An increased dose of dipyrone (50 mg/kg, i.v.) was required to attenuate this IL-1 beta fever; however, the PGE fever remained unaffected by this treatment with dipyrone. Thus, dipyrone treatment blocks IL-1 beta fever where synthesis of prostaglandin is a crucial step in the febrile process, but it has no effect on PGE fever where synthesis is bypassed. This suggests that dipyrone, probably through its active metabolites, inhibits prostaglandin synthesis to induce antipyresis and, by analogy, analgesia as well.
Similar articles
-
Site of action of calcium channel blockers in inhibiting endogenous pyrogen fever in rats.J Appl Physiol (1985). 1991 Sep;71(3):956-60. doi: 10.1152/jappl.1991.71.3.956. J Appl Physiol (1985). 1991. PMID: 1757334
-
The antipyretic effect of dipyrone is unrelated to inhibition of PGE(2) synthesis in the hypothalamus.Br J Pharmacol. 2011 Mar;162(6):1401-9. doi: 10.1111/j.1476-5381.2010.01150.x. Br J Pharmacol. 2011. PMID: 21133897 Free PMC article.
-
Functional and structural differences in febrile mechanism between rabbits and rats.J Physiol. 1990 Aug;427:227-39. doi: 10.1113/jphysiol.1990.sp018169. J Physiol. 1990. PMID: 2213598 Free PMC article.
-
Passage of immunomodulators across the blood-brain barrier.Yale J Biol Med. 1990 Mar-Apr;63(2):121-31. Yale J Biol Med. 1990. PMID: 2119089 Free PMC article. Review.
-
Endogenous pyrogens in the CNS: role in the febrile response.Prog Brain Res. 1992;93:419-28; discussion 428-9. doi: 10.1016/s0079-6123(08)64587-2. Prog Brain Res. 1992. PMID: 1480760 Review.
Cited by
-
Randomized trial of the effect of antipyresis by metamizol, propacetamol or external cooling on metabolism, hemodynamics and inflammatory response.Intensive Care Med. 2004 Mar;30(3):401-7. doi: 10.1007/s00134-003-2087-2. Epub 2004 Jan 13. Intensive Care Med. 2004. PMID: 14722642 Clinical Trial.
-
Study of DNA damage caused by dipyrone in presence of some transition metal ions.Saudi Pharm J. 2017 Nov;25(7):961-966. doi: 10.1016/j.jsps.2017.02.010. Epub 2017 Feb 27. Saudi Pharm J. 2017. PMID: 29158701 Free PMC article.
-
Dipyrone metabolite 4-MAA induces hypothermia and inhibits PGE2 -dependent and -independent fever while 4-AA only blocks PGE2 -dependent fever.Br J Pharmacol. 2014 Aug;171(15):3666-79. doi: 10.1111/bph.12717. Br J Pharmacol. 2014. PMID: 24712707 Free PMC article.
-
Novel bioactive metabolites of dipyrone (metamizol).Bioorg Med Chem. 2012 Jan 1;20(1):101-7. doi: 10.1016/j.bmc.2011.11.028. Epub 2011 Nov 25. Bioorg Med Chem. 2012. PMID: 22172309 Free PMC article.
-
Hypersensitivity to pyrazolones.Thorax. 2000 Oct;55 Suppl 2(Suppl 2):S72-4. doi: 10.1136/thorax.55.suppl_2.s72. Thorax. 2000. PMID: 10992566 Free PMC article. Review. No abstract available.